English, Article edition: Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox(R)/Asasantin(R)) in France Jean-Pierre Marissal; Bernard Selke

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119011
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox(R)/​Asasantin(R)) in France
Author
  • Jean-Pierre Marissal
  • Bernard Selke
Physical Description
  • article
Notes
  • Objective: To assess the cost effectiveness of aspirin 25mg plus dipyridamole 200mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2). The ESPS-2 was a double-blind, placebo-controlled clinical trial which assessed the efficacy of four secondary prevention strategies: (i) placebo; (ii) aspirin (acetylsalicylic acid) 25mg twice daily; (iii) dipyridamole 200mg twice daily; and (iv) aspirin 25mg plus dipyridamole 200mg twice daily. Method: We performed a cost-effectiveness analysis with Monte Carlo simulations to compute confidence intervals. We combined data from various sources including the Dijon Stroke Registry, Institut National de la Statistique et des Etudes Economiques, Etude du Cout de l'Infarctus Cerebral (Study of the Cost of Cerebral Infarction [ECIC]) study and the ESPS-2 trial. Results: According to our findings, a preventive strategy with aspirin 25mg plus dipyridamole 200mg twice daily is associated with net benefits per avoided stroke recurrence amounting to $US23 Conclusions: In the secondary prevention of stroke in France, this study suggests, given its underlying assumptions and data, that aspirin 25mg plus dipyridamole 200mg twice daily is likely to be a cost-effective strategy from the social security perspective, when compared with other relevant strategies that were evaluated in the ESPS-2 trial.
  • Aspirin, Cost-effectiveness, Dipyridamole, Stroke
  • RePEc:wkh:phecon:v:22:y:2004:i:10:p:661-670
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment